While narrative is crucial for IPOs, raises exceeding $50 billion cannot be sustained by marketing alone. The sheer volume of capital required necessitates deep scrutiny from institutional investors, making strong financials and fundamentals the ultimate deciding factor, unlike smaller, easily inflated offerings.

An IPO at a valuation that's flat compared to the last private round suggests the company is distressed. It implies the private markets are tapped out and the company is being forced to go public out of a desperate need for capital, rather than from a position of strength.

The reopening of the biotech IPO market is fragile. A key risk identified by investors is a series of failed IPOs, which could halt the sector's positive momentum. Consequently, there is intense pressure on bankers and VCs to exhibit "quality discipline," ensuring that only the most mature and high-potential companies go public first to build a track record of success.

Venture capitalist Bruce Booth explains that bankers, lawyers, audit firms, and VCs all have strong financial incentives for a company to go public. This creates systemic pressure that may not align with the company's best long-term interests.

When a high-profile IPO like SpaceX reserves a large portion (30%) for retail investors, it may not be about democratization. This can be a strategic move to offload shares at an inflated price to emotionally invested fans rather than price-sensitive institutional analysts.

The first-day surge in an IPO's stock price represents value transferred from the company to institutional investors who bought at a deliberately underpriced offering price. Retail investors who buy after this 'pop' are often left purchasing inflated shares while insiders cash out on the manufactured frenzy.

For many large companies today, an IPO's primary purpose has shifted from raising growth capital—which is readily available in private markets—to creating liquidity for early investors and employees. The public offering acts as a valuation marker and an exit opportunity, not a funding necessity.

Unlike in tech where an IPO is often a liquidity event for early investors, a biotech IPO is an "entrance." It functions as a financing round to bring in public market capital needed for expensive late-stage trials. The true exit for investors is typically a future acquisition.

Contrary to popular belief, an IPO should not be viewed as a liquidity event. Instead, its primary value is in marketing and branding. It signals to the market, customers, and potential employees that the company is stable and "here to stay." The actual liquidity is often constrained by lockups and regulations.